Autologous Stem Cell Transplantation for Amyloidosis Patient

17 Oct Autologous Stem Cell Transplantation for Amyloidosis Patient

Posted at 09:12h in Blog, R3 Stem Cell International, Regenerative Medicine, stem cell therapy by siteadmin 0 Comments

0 Likes

Light chain amyloidosis results from clonal plasma cells; however, cell therapy directed against these clone cells has remained the most effective treatment for the condition. Over time, autologous stem cell transplantation (ASCT) has become a critical treatment resource for addressing light-chain amyloidosis.

Following ASCT, patients with a standard white blood cell and platelet count have shown a longer overall survival rate. But what exactly is amyloidosis, and why is autologous stem cell transplantation an effective treatment?

WHAT IS AMYLOIDOSIS?

Amyloidosis is a rare condition that occurs when amyloid – an abnormal protein, builds up in the tissues and organs. Following this build-up, the organs could stop functioning normally. The heart, kidneys, liver, spleen, digestive tract, and nervous system are some common organs affected by amyloidosis. It’s quite common for amyloidosis to occur with other illnesses and may improve with treatment. However, there is a strong possibility it could result in critical organ failure if it’s not addressed in time. A well-known remedy for this condition is chemotherapy with strong cancer medications to reduce symptoms and control amyloid production. Nonetheless, a more effective treatment is stem cell transplants.

SYMPTOMS OF AMYLOIDOSIS

It takes a considerable amount of time before amyloidosis symptoms begin to show. These symptoms also vary, depending on the affected organs. However, some known symptoms include the following;

Shortness of breath
Ankles and legs swelling
Diarrhea and constipation, possibly with blood.
Acute weakness and fatigue
Skin changes, including thick bruising and purple patches around the eye
An enlarged tongue with wrinkled edges

Amyloidosis is very rare, and some of its risk factors include age, sex, race, kidney dialysis, family history, and other severe medical conditions. If any of the symptoms associated with this condition is experienced, a medical professional should be seen immediately.

AUTOLOGOUS STEM CELL TRANSPLANT

Pairing high-dose chemotherapy with an autologous stem cell transplant has been found to be effective in triggering complete remissions in a high number of patients. This has led to ASCT being adopted for the systemic treatment of AL amyloidosis.

In truth, autologous stem cell transplant is associated with a consistently high hematologic response rate – a normal count of white blood cells and platelets. This evidently leads to improved organ function, survival, and a better quality of life. Based on previous tests, this therapy yields better results from previous tests in patients with one to two organ functions and no cardiac defect. However, this therapy is unsuitable for patients with over two organ involvement and cardiac involvement.

This highlights the importance of patient selection in ASCT to ensure safety and optimal outcome. Autologous stem cell transplant should only be administered to patients who are healthy enough to endure it. While ASCT remains an effective treatment for AL amyloidosis, its evolution remains probable in order to generate more effective therapy.

R3 Stem Cell offers autologous stem cell transplant therapy in Phoenix, AZ. Our centers have professionals who can carry out diagnostics for accurate patient selection and deliver stem cell therapy to treat and reduce the symptoms of amyloidosis. Contact us today.

ABOUT US

The information provided by R3 Stem Cell is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and only your medical professional can explain all the risks and potential benefits of any therapy based on your circumstances. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.